License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness.
Prevymis wins CHMP nod for CMV disease in kidney transplant patients – Pharmaceutical Technology
The CHMP decision could now expand the approval to patients at risk of CMV infection during kidney transplants in the EU. Image credit: Shutterstock/Explode. The
October 18, 2023